TY - JOUR
T1 - Validation of the Integrated Palliative care Outcome Scale (IPOS) – Japanese Version
AU - Sakurai, Hiroki
AU - Miyashita, Mitsunori
AU - Imai, Kengo
AU - Miyamoto, Shingo
AU - Otani, Hiroyuki
AU - Oishi, Ai
AU - Kizawa, Yoshiyuki
AU - Matsushima, Eisuke
N1 - Funding Information:
This work was supported by the Sasakawa Memorial Health Foundation [Grant numbers 2013a001, 2016a003]. The funding source is not involved in the planning, conduct or analysis of this study.
Publisher Copyright:
© The Author(s) 2019. Published by Oxford University Press. All rights reserved.
PY - 2019/3/1
Y1 - 2019/3/1
N2 - Background: To improve palliative care practice, the need for patients-reported outcome measures is increasing globally. The Integrated Palliative care Outcome Scale (IPOS) is a streamlined outcome scale developed to comprehensively evaluate patients’ distress. The goal of this study is to assess the reliability and validity of IPOS-Japanese version in cancer patients. Methods: This is a multicenter, cross-sectional observational study. We assessed the missing values, prevalence, test–retest reliability, criterion validity and known-group validity in Japanese adult cancer patients. Patients provided responses to IPOS, European Organization for Research and Treatment for Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), and Functional Assessment of Chronic Illness Therapy- Spiritual 12 (FACIT-Sp12). Our medical staff provided responses to Support Team Assessment Schedule (STAS). Results: One hundred forty-two patients were enrolled at six palliative care facilities. Missing values accounted for less than 1% of most items, with a maximum of 2.8%. The prevalence of symptoms was 17.7–88.7%. The intra-class correlation coefficient ranged from 0.522 to 0.951. The range of correlation coefficients with EORTC-QLQ-C30, FACIT-Sp12 and STAS as gold standards was 0.013 to 0.864 (absolute values). Total IPOS scores were positively correlated with Eastern Corporative Oncology Group Performance Status (P < 0.001). Conclusion: IPOS-Japanese version is a valid and reliable tool. The scale is useful in assessing physical, psychological, social and spiritual symptoms and in measuring outcomes of adult cancer patients in Japan.
AB - Background: To improve palliative care practice, the need for patients-reported outcome measures is increasing globally. The Integrated Palliative care Outcome Scale (IPOS) is a streamlined outcome scale developed to comprehensively evaluate patients’ distress. The goal of this study is to assess the reliability and validity of IPOS-Japanese version in cancer patients. Methods: This is a multicenter, cross-sectional observational study. We assessed the missing values, prevalence, test–retest reliability, criterion validity and known-group validity in Japanese adult cancer patients. Patients provided responses to IPOS, European Organization for Research and Treatment for Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), and Functional Assessment of Chronic Illness Therapy- Spiritual 12 (FACIT-Sp12). Our medical staff provided responses to Support Team Assessment Schedule (STAS). Results: One hundred forty-two patients were enrolled at six palliative care facilities. Missing values accounted for less than 1% of most items, with a maximum of 2.8%. The prevalence of symptoms was 17.7–88.7%. The intra-class correlation coefficient ranged from 0.522 to 0.951. The range of correlation coefficients with EORTC-QLQ-C30, FACIT-Sp12 and STAS as gold standards was 0.013 to 0.864 (absolute values). Total IPOS scores were positively correlated with Eastern Corporative Oncology Group Performance Status (P < 0.001). Conclusion: IPOS-Japanese version is a valid and reliable tool. The scale is useful in assessing physical, psychological, social and spiritual symptoms and in measuring outcomes of adult cancer patients in Japan.
KW - Integrated Palliative care Outcome Scale
KW - Japanese version
KW - Reliability
KW - Validation
KW - Validity
UR - http://www.scopus.com/inward/record.url?scp=85063955019&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063955019&partnerID=8YFLogxK
U2 - 10.1093/jjco/hyy203
DO - 10.1093/jjco/hyy203
M3 - Article
C2 - 30668720
AN - SCOPUS:85063955019
VL - 49
SP - 257
EP - 262
JO - Japanese Journal of Clinical Oncology
JF - Japanese Journal of Clinical Oncology
SN - 0368-2811
IS - 3
ER -